
For the final episode of Season 1 of @DevAndResearch, I'm sitting down with Ambassador Mark Dybul—one of the architects of the President's Emergency Plan for AIDS Relief—who argues that America has forgotten the core insight of the Marshall Plan: supporting other countries' economic growth creates markets for American businesses, not competition for American workers. We talk about drug development, too: • why many drugs don't work in women and people of color • how buying HIV drugs for Africa led to improved treatments for Americans • whether the FDA was wrong to reject MDMA for PTSD • the changes that could cut drug development expenses by orders of magnitude while producing treatments that actually work for everyone, supporting American geopolitical dominance, and defusing geopolitical instabilities that will “make pandemics looks like child’s play” 01:40 Introduction 02:20 PEPFAR’s systemic legacy 06:48 Why we make drugs that don’t work 10:18 PEPFAR’s legacy in the private sector 12:38 Covid lessons we failed to learn 16:33 MDMA for PTSD: Was the FDA wrong? 23:35 The President: “I want it to be big.” 26:22 A Marshall Plan for the 21st Century 29:00 US companies don’t understand Africa 37:02 Global-first drug development 45:45 What has Covid changed? 50:22 Global-health investment is stuck in the past 52:23 Immunotherapy and the Future of Medicine 58:03 What’s holding back change? 01:01:47 The Way Forward



